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Introduction: Bevacizumab improves survival in patients with 
advanced non–small-cell lung cancer (NSCLC). This phase II clini-
cal trial assessed the effects of the addition of bevacizumab to neoad-
juvant chemotherapy in resectable nonsquamous NSCLC.
Methods: Patients with resectable stage IB–IIIA nonsquamous 
NSCLC were treated with bevacizumab followed by imaging 2 
weeks later to assess single-agent effect. After this they received two 
cycles of bevacizumab with four cycles of cisplatin and docetaxel 
followed by surgical resection. Resected patients were eligible for 
adjuvant bevacizumab. The primary endpoint was the rate of patho-
logical downstaging (decrease from pretreatment clinical stage to 
post-treatment pathological stage). Secondary endpoints included 
overall survival, safety, and radiologic response.
Results: Fifty patients were enrolled. Thirty-four (68%) were clinical 
stage IIIA. All three doses of neoadjuvant bevacizumab were deliv-
ered to 40 of 50 patients. Six patients (12%) discontinued because of 
bevacizumab-related adverse events. The rate of downstaging (38%), 
response to chemotherapy (45%), and perioperative complications 
(12%) were comparable with historical data. No partial responses 
were observed to single-agent bevacizumab, but 18% of the patients 
developed new intratumoral cavitation, with a trend toward improved 
pathologic response (57% versus 21%; p = 0.07). A major pathologic 
response (≥90% treatment effect) was associated with survival at 3 
years (100% versus 49%; p = 0.01). No patients with KRAS-mutant 
NSCLC (0 of 10) had a pathologic response as compared with 11 of 
31 with wild-type KRAS.
Conclusion: Although preoperative bevacizumab plus chemotherapy 
was feasible, it did not improve downstaging in unselected patients. 
New cavitation after single-agent bevacizumab is a potential bio-
marker. Alternative strategies are needed for KRAS-mutant tumors.
Key Words: Neoadjuvant chemotherapy, Non–small-cell lung can-
cer, Bevacizumab, Surgery, Pathologic response.
(J Thorac Oncol. 2013;8: 1084-1090)
Patients with stage IB–IIIA non–small-cell lung cancers (NSCLCs) are potentially curable with a multimodality 
approach, however, 5-year survival rates remain disappoint-
ing: 67% for stage I, 54% for stage II, and 40% for stage 
III.1 The use of neoadjuvant therapy followed by surgery has 
the advantage of allowing administration of 90% of planned 
cisplatin-based chemotherapy compared with 50% of planned 
treatment in the postoperative setting without any increase in 
surgical risk.2 This approach provides earlier systemic therapy 
for the treatment of micrometastatic disease and allows for an 
assessment of treatment efficacy in each individual patient. 
Ineffective therapies can be stopped and alternative drugs 
substituted. Neoadjuvant therapy also allows for an in vivo 
evaluation of new therapeutic approaches, providing critical 
information for drug development, because response to ther-
apy can be assessed both radiographically and correlatively in 
post-treatment pathologic specimens.
Although disease free survival (DFS) and overall survival 
(OS) remain the gold standard for evaluation of perioperative 
interventions, surrogate endpoints can provide an earlier esti-
mation of the effectiveness of new therapies. In particular, the 
downstaging from pretreatment to post-treatment stage and 
pathological response to neoadjuvant chemotherapy have con-
sistently correlated with survival in neoadjuvant clinical trials.3–7
Bevacizumab is a recombinant humanized monoclonal 
antibody that binds to vascular endothelial growth factor A. 
In combination with chemotherapy in stage IV nonsquamous 
NSCLC, bevacizumab improved the objective response rate 
from 15% to 35% and OS from 10 to 12 months.8 We sought 
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to evaluate whether perioperative bevacizumab would be of 
benefit to patients with resectable stage IB–IIIA nonsquamous 
NSCLC.
The primary endpoint of this study was to determine 
whether the addition of bevacizumab to neoadjuvant chemo-
therapy improved downstaging from clinical to pathological 
stage compared with historical controls.9 The secondary end-
points included safety, evaluation of pathological and radio-
logical response, time to progression (TTP), recurrence-free 
survival (RFS), and OS of all patients and of the subset with 
stage IIIA disease.
PATIENTS AND METHODS
Study Design
This was a single-institution phase II study. The schema 
is presented in Figure 1. The primary endpoint was the rate of 
downstaging in patients with clinical stage IB–IIIA nonsqua-
mous NSCLC treated with neoadjuvant docetaxel and cisplatin 
chemotherapy in combination with bevacizumab. Downstaging 
was defined as any decrease in the final pathologic stage when 
compared with the clinical stage (before neoadjuvant therapy). 
Secondary endpoints included safety, radiologic response to 
single-agent bevacizumab, radiologic response to chemother-
apy, TTP, and OS from the start of chemotherapy, and RFS 
from the date of complete resection. The survival endpoints 
included analysis in all patients and in the subset with stage 
IIIA disease. This protocol was approved by the institutional 
review board, and all patients signed informed consent.
Patients
Eligible patients had pathologically confirmed nonsqua-
mous NSCLC of clinical stages IB–IIIA (T1-3N0-2M0) by 
American Joint Committee on Cancer Staging 6th edition. 
Pretreatment evaluation included chest computed tomogra-
phy (CT), positron emission tomography scan, brain mag-
netic resonance imaging, and pathologic mediastinal staging 
(mediastinoscopy or endobronchial ultrasound), if clinically 
indicated. Patients were required to have a Karnofsky perfor-
mance status of 70% or more, adequate organ function, and 
be considered resectable by a thoracic surgeon. Patients were 
ineligible if they had large central tumors, were receiving anti-
coagulation medication, had a history of hemoptysis, stroke, 
or myocardial infarction within the past year, uncontrolled 
hypertension, nonhealing wound/ulcer/fracture, hearing loss, 
or peripheral neuropathy more than grade 1.
Preoperative Treatment
The first dose of bevacizumab (15 mg/kg) was adminis-
tered 2 weeks before cisplatin and docetaxel to allow assess-
ment of the radiographic effects of bevacizumab alone. 
Patients received four cycles of docetaxel (75 mg/m2) and cis-
platin (75 mg/m2) intravenously every 21 days. Cycles 2 and 3 
of docetaxel, cisplatin, and bevacizumab were administered on 
the same day. Bevacizumab was omitted from cycle 4 (Fig. 1). 
Pegfilgrastim was administered prophylactically at the discre-
tion of the investigator. Toxicities were graded using National 
Cancer Institute Common Toxicity Criteria, version 3.0.
Surgery and Analyses
Patients were re-evaluated for surgery by clinical 
examination, chest CT, positron emission tomography scan, 
pulmonary function tests, and brain magnetic resonance imag-
ing. Radiographic response was assessed using Response 
Evaluation Criteria in Solid Tumors.10 Surgical exploration, 
resection, and mediastinal lymph node dissection occurred 3 
to 8 weeks after chemotherapy and 6 weeks or more after the 
last bevacizumab. The surgical specimens were reviewed by 
one thoracic pathologist (WDT). Tumors were representatively 
sampled with one section per centimeter diameter of the tumor, 
examined by light microscopy for histologic diagnosis and the 
extent of the effect of treatment, including necrosis, fibrosis, 
and inflammation. The treatment effect was semiquantitatively 
estimated in 10% increments. Molecular analyses were per-
formed for mutations in Epidermal Growth Factor Receptor 
and KRAS per standard methods.11,12
Postoperative Treatment and Follow-Up
Adjuvant bevacizumab (15 mg/kg) was administered 
intravenously starting from day 42 to 56 postoperatively and 
continued every 21 days for 1 year (18 cycles). If postopera-
tive radiotherapy was indicated based on N2 nodal involve-
ment or a positive resection margin, bevacizumab was delayed 
until day 28 to 52 after the completion of radiation. No other 
chemotherapy was given postoperatively.
Patients were followed for disease recurrence with 
history, physical examination, and CT scans of the chest and 
Docetaxel + 
Cisplatin
Bevacizumab
Surgery Adjuvant Bevacizumab
Bevacizumab 
response
0        2       4       6        8       10     12     14     16     18      20 ---------------------------------------72 weeks
FIGURE 1.  Treatment schema.
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upper abdomen every 4 months for 2 years, every 6 months 
for the third year, and annually thereafter.
Outcome Analysis
The primary endpoint was an improvement in downstag-
ing from the published rate of 33%9 to the target rate of 50%. 
A sample size of 50 patients was chosen to allow distinction 
between 33% and 50% downstaging rates, with one-sided type 
I and type II error rates of 11.6% and 10.2%, respectively. With 
these parameters, the trial would be considered successful if at 
least 21 of 50 patients were downstaged. Patients who were not 
resected were counted as not downstaged. Early stopping rules 
were in effect in case excessive toxicity was observed.
In this study, we evaluated OS and TTP in all patients, 
from the start of neoadjuvant chemotherapy and RFS in 
patients, who underwent surgical resection, from the date of 
surgery. Patients were followed until death in OS analyses; 
until time to documented progression in the TTP analysis; 
and until death or disease recurrence, whichever came first, 
in the RFS analysis. Patients who did not experience the 
event of interest were censored at the time of the last avail-
able follow-up. All time-to-event outcomes were estimated 
using Kaplan–Meier method. Planned subgroup analyses 
were restricted to the subset with clinical stage IIIA disease. 
Clinical outcomes after surgery were compared by downstag-
ing, nodal downstaging (in patients with clinical N1 or N2 dis-
ease), pathological response, and radiological response, using 
nonparametric log-rank test. Analyses based on intratumoral 
cavitation and KRAS status were unplanned and exploratory. 
Two-by-two comparisons were performed using fisher’s exact 
test. Statistical analyses were performed using SAS software 
(version 9.2; SAS Institute Inc., Cary, NC) and R (version 
2.14.1; R Development Core Team, 2011).
RESULTS
Patient Characteristics
Fifty patients were enrolled between August 2005 and 
April 2011. Baseline patient characteristics are summarized 
in Table 1. The flow of patients screened, treated, and analyzed 
is presented in Figure 2.
Primary Endpoint-Downstaging
The primary endpoint of the study was downstaging. 
Given that unresected patients were considered as treatment 
failures, 19 of 50 patients enrolled were downstaged, this rate 
of 38% (95% confidence interval [CI], 25% –53%) did not 
meet the primary endpoint of the study. Downstaging from 
clinical to pathological stage included 14 patients with stage 
IIIA (pathologic 5 IA, 4 IB, 3 IIA, and 2 IIB), one patient 
with stage IIB (with complete pathologic response to stage 0), 
two patients with IIA (pathologic stage IA and IB), and two 
patients with stage IB (pathologic stage IA).
Chemotherapy Compliance and Toxicity
Chemotherapy cycles delivered and reasons for drug 
discontinuation are listed in Table 2. Of 42 patients who com-
pleted all four cycles of chemotherapy, 32 received full-dose 
treatment. Ten patients required dose reductions for febrile 
neutropenia (2), neutropenia without fever (3), fatigue (3), and 
mucositis/colitis (2).
Thirty-one patients received prophylactic pegfilgrastim. 
There was one treatment-related death with the first cycle of 
chemotherapy attributed to neutropenic sepsis in a patient 
who did not receive prophylactic pegfilgrastim. Grade 3 or 
4 neutropenia occurred in 15 patients (30%), and there were 
four cases (8%) of febrile neutropenia. One patient had a cavi-
tary pneumonia. Anemia and thrombocytopenia were uncom-
mon, with 12% and 8% of patients experiencing grade 3 and 
4 toxicities, respectively. There was one patient with transient 
grade 4 hepatotoxicity. There were two grade 2 allergic reac-
tions to docetaxel. Thirty-one patients (62%) had grade 1 or 2 
fatigue or malaise, and 11 (22%) experienced grade 3 fatigue. 
The toxicities in Table 2 potentially attributable to neoadju-
vant bevacizumab, totaled 16% with four cases of grade 1 or 
2 hemoptysis, one grade 3 hypertension, one grade 4 colitis 
with perforation (after third dose), one cavitary pneumonia, 
and a single death from neutropenic sepsis.
Radiographic Responses
The CT responses measured 2 weeks after single agent 
bevacizumab are depicted in Figure 3. The median regression 
seen was −7% (range, +8% to −24%). There were no partial 
TABLE 1.  Patient Characteristics
Characteristic n (%)
Age, median (yr, range) 61 (45–77)
Men 20 (40)
Women 30 (60)
Smoking history
 Never 2 (4)
 Former 27 (54)
 Current 21 (42)
Pack-years–median (range) 36 (0–150)
Clinical stage
 IB 6 (12)
 IIA 5 (10)
 IIB 5 (10)
 IIIA 34 (68)
Mediastinal staging
 Mediastinoscopy 15 (30)
 Endobronchial ultrasound 5 (10)
Histology
 Adenocarcinoma 45 (90)
 Large-cell neuroendocrine 
carcinoma
4 (8)
 Adenosquamous carcinoma 1 (2)
Molecular profile
 EGFR mutation 4 (8)
 KRAS mutation 13 (26)
 EGFR/KRAS wild-type 30 (60)
 Insufficient for molecular analysis 3 (6)
EGFR, epidermal growth factor receptor. 
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responses. Nine patients (shown in red in Fig. 3) developed 
cavitation after a single dose of bevacizumab.
Forty-four patients had CT scans of the chest with mea-
surable disease both pretreatment and after completion of 
neoadjuvant chemotherapy; 20 had a partial response, for an 
objective response rate of 45% (95% CI, 30% –to 61%).
Surgery and Postoperative Complications
Forty-four of 50 patients had surgery. Patients did not 
have surgery because of death as a result of chemotherapy tox-
icity (1), development of metastatic disease (3), inadequate 
pulmonary reserve to tolerate resection (1), and withdrawal of 
consent (1). Of 44 patients, three were found to have unresect-
able disease. Forty-one patients were resected with 4 pneumo-
nectomies (2 right and 2 left) (8%), 3 bilobectomies (6%), 32 
lobectomies (64%), and 2 wedge resections (4%). Resection 
was complete (R0) in 36 patients (82% of those explored; 
72% of those enrolled) and incomplete in 5 patients (3 R1 and 
2 R2 resections).
There were no perioperative deaths. Immediate 
postoperative complications included single cases of 
gastrointestinal bleed, volvulus, bronchopleural fistula, and 
empyema, all grade 3. Late postoperative complications 
included one patient with a bronchopleural fistula and one with 
an infected mesh. Empyema and infected mesh were considered 
to be unrelated to bevacizumab, therefore, perioperative 
complications at least potentially attributable to preoperative 
bevacizumab among patients with attempted resection totaled 
9% (4 of 44) (95% CI, 11%–35%).
Adjuvant Therapy and Complications
Thirteen of the 41 patients who had surgical resection 
received postoperative radiation therapy. Nine of these patients 
had involved N2 nodes and six had positive resection margins.
Eligible (n=50)
Excluded (n=6)
Refused surgery (n=1)*
Medically inoperable (n=1)*
Chemotherapy complication (n=1)*
Preoperative Progression (n=3)
Adjuvant
bevacizumab
Neoadjuvant
chemotherapy
Attempted Resection –
Analyzed (n=44)
Enrollment
Unresectable (n=3)
Resected (n=41)
Excluded (n=22)
Refused (n=5)
Post-operative complications (n=4)
GI contraindication (n=3)
Disease Progression (n=8)
Docetaxel reaction (n=2)
Adjuvant Bevacizumab 
(n=19)
Surgery
*3 patients excluded from primary endpoint (1 refused surgery, 1 medically 
inoperable, 1 chemotherapy-related death)
Screened (n=363)
Excluded (n=313)
Not NSCLC (n=17)
Eligible but did not enroll (n=153)
Stage (IA =7; IIIB/IV=82)
Medically ineligible (n=26)
Enrolled on alternative trial (n=28)
FIGURE 2.  Flow of patients. NSCLC, non–small-cell lung cancer; GI, gastrointestinal.
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Thirty-nine patients were eligible to receive adjuvant 
bevacizumab, as outlined in Figure 2. Nineteen of 39 patients 
received postoperative bevacizumab. The median number of 
cycles was 17 (range, 1–18). Toxicities and reasons for discon-
tinuation of adjuvant bevacizumab are summarized in Table 2.
Clinical Outcomes
With a median follow-up of 29 months at the time of 
analysis, 25 of 50 patients experienced disease progression. In 
patients who underwent resection, all observed deaths were in 
patients with recurrent disease. The median OS after start of 
neoadjuvant therapy was not reached for the entire cohort, and 
the 3-year OS was 64% (95% CI, 51%–79%). Median TTP 
after start of chemotherapy was 49 months (95% CI, 18 to not 
reached), with 53% (95% CI, 40%–70%) of patients being 
progression-free at 3 years. In patients with clinical stage IIIA 
disease (n = 34), the median OS was 37 months (95% CI, 14–
not reached), the 3-year OS was 52% (95% CI, 38%–72%), the 
median TTP was 20 months (95% CI, 8–not reached), and 42% 
(95% CI, 28%–63%) were progression-free at 3 years.
Among the 41 patients who underwent resection, the 
median follow-up after surgery was 29 months, during which 
14 patients died. The median RFS was 54 months (95% CI, 
24 to not reached), median OS was not reached, and 3-year 
OS was 62% (95% CI, 48%–80%). Among patients with stage 
IIIA, the median RFS was 30 months (95% CI, 9–not reached), 
median OS was 35 months (95% CI, 18–not reached), and 
3-year OS was 50% (95% CI, 34%–74%).
In resected patients, downstaging was not associated with 
improved OS after resection (3-year OS = 70% versus 56% 
in the group without downstaging; p = 0.24) or RFS (3-year 
RFS = 65% versus 52% in the group without downstaging; p = 
0.52). Nodal downstaging was marginally associated with 
improved OS (3-year OS = 66% versus 37%; p = 0.051) but did 
not increase RFS (3-year RFS = 54% versus 37%; p = 0.40).
Exploratory Outcomes
Among the 41 resected patients, 11 (27%; 95% CI, 
14%–43%) had 90% or higher pathologic response. Pathologic 
response did correlate with outcomes. In 11 of 41 patients 
(27%) with 90% or more versus those with less than 90% 
treatment effect, the 3-year RFS was 91% versus 48%; p value 
is equal to 0.024 and OS 100% versus 49%; p value is equal 
to 0.011. These outcomes remained significant when adjusted 
for clinical stage (p = 0.035 and 0.018, respectively).
TABLE 2.  Chemotherapy Delivery
Drug Cycles N Dose-Limiting Event (n)
Bevacizumab
 3 40 Diverticulitis with perforation(1)
 2 2 Hemoptysis(1), hypertension(1)
 1 8 Hemoptysis(3), cavitary PNA(1), docetaxel 
reaction (2), sepsis/death(1), sepsis/ 
pneumonitis(1)
Docetaxel/cisplatin
 4 42
 3 3 Transaminitis(1), fatigue(1)
 2 0
 1 5 Cavitary PNA(1), docetaxel reaction(2), 
sepsis/death(1), sepsis/pneumonitis(1)
Adjuvant bevacizumab
 18 9
 17 2 Patient preference(2)
 14 1 Hemoptysis
 13 2 Fatigue(1), withdrew consent(1)
 10 1 EKG changes
 4–7 3 Progression of disease(3)
 1 1 Hypertensive urgency
EKG, electrocardiogram; PNA, pneumonia.
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FIGURE 3.  Percentage change in 
tumor burden 2 weeks after beva-
cizumab per RECIST v1.1 criteria. 
Patients with new intratumoral cavita-
tion shown in red.
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Intratumoral cavitation after one dose of bevacizumab 
was associated with a trend toward improved pathologic 
response, whereas KRAS mutation predicted lack of response, 
as outlined in Table 3.
DISCUSSION
This study represents the first published trial evaluat-
ing the addition of neoadjuvant bevacizumab to chemotherapy 
as part of a combined modality approach to the treatment of 
patients, with resectable stage IB–IIIA NSCLC. Randomized 
multimodality trials have demonstrated a 10% to 30% survival 
advantage with the use of adjuvant or neoadjuvant chemother-
apy over surgery alone.2,13–19 The debate remains as to whether 
neoadjuvant or adjuvant chemotherapy is the best approach, 
with advantages and disadvantages to each. Adjuvant treat-
ment has the advantage of providing clinicians with a patho-
logic stage to guide postoperative therapy recommendations. 
Although upfront surgery guarantees adequate tissue for molec-
ular studies, current targeted therapies (such as erlotinib in 
EGFR–mutant NSCLC) remain investigational in the adjuvant 
setting and are being studied only after completion of standard 
therapies. The main disadvantage of adjuvant chemotherapy 
is the difficulty of drug delivery, postoperatively.2 For clinical 
investigation, administration of neoadjuvant chemotherapy 
allows for an in vivo assessment of treatment response radio-
logically and pathologically, and the use of surrogate endpoints, 
such as downstaging and pathologic response.
In this trial, we added bevacizumab to neoadjuvant che-
motherapy in patients with resectable NSCLC in an attempt to 
improve the rate of downstaging.9 With 38% of patients show-
ing an improvement from initial clinical to final pathological 
stage, this study failed to meet its primary endpoint (an increase 
from the reported 33%9 to a goal of 50%). From the start of che-
motherapy, the median survival of patients with clinical stage 
IIIA NSCLC was 37 months, which is comparable with that 
reported in previously published neoadjuvant trials.4
This study has many limitations. With concerns for 
bevacizumab-related toxicities, this study had many strict 
eligibility criteria. As a single-institution study, these criteria 
slowed the anticipated rate of accrual. Strict eligibility criteria 
also raise questions about potential confounders when com-
pared with historical controls, as patients with many common 
comorbid illnesses were not included. Finally, and perhaps the 
largest limitation was the selection of the primary endpoint 
in the absence of uniform mediastinal staging. Although the 
data for downstaging were compelling and allowed for inclu-
sion of lymph node–negative patients who would otherwise 
be appropriate for neoadjuvant chemotherapy, the lack of uni-
form pathological (mediastinal) staging on all patients may 
have induced bias in the results. Alternative endpoints, such 
as pathologic response, may have better correlated with long-
term outcomes such as RFS and OS and been just as reliable, 
regardless of pretreatment stage. Despite these limitations 
and failure to meet the primary endpoint, this study has many 
informative observations.
Neoadjuvant bevacizumab was generally well tolerated. 
Uncomplicated hemoptysis was the most common reason for 
bevacizumab discontinuation, and there was no evidence of 
increased chemotherapy toxicity because of the combination. 
There was one grade 4 diverticulitis with perforation and one 
death from infection in the setting of treatment-related neutro-
penia. Bevacizumab has been associated with diverticulitis and 
shown to increase chemotherapy-induced neutropenia.8 The 
early stopping criteria were not met. Perioperative complica-
tions potentially attributable to bevacizumab included gastro-
intestinal bleeding and bronchopleural fistulization. Although 
the gastrointestinal complication rate is higher than expected 
after standard neoadjuvant chemotherapy without bevaci-
zumab followed by thoracic surgery, the overall perioperative 
morbidity was comparable with what has been published.20 
After induction treatment and surgery, the delivery of beva-
cizumab was not feasible with approximately half of eligible 
patients (19 of 39) receiving any adjuvant therapy (Fig. 2).
In patients with clinical stage IIIA (N2), both clinical 
and nodal downstaging have been shown to be pathological 
correlates of clinical outcomes.3–5 In this trial, 82% of 
enrolled patients (41 of 50) were resected after neoadjuvant 
chemotherapy. There was no association between downstaging 
or nodal downstaging with survival. Alternative surrogate 
endpoints include pathologic response, defined as treatment 
effect of more than 90%. Junker et al.21 described pathological 
response as predictive of outcomes after multimodality 
therapy with patients left with less than 10% viable tumor cells 
TABLE 3.  Exploratory Analyses (Only Resected Patients 
Included)
Outcome
Cavitation  
(n = 7)
No Cavitation  
(n = 34) p
Downstaged 5 (71%) 14 (41%) —
Not downstaged 2 (29%) 20 (59%) 0.22
Nodal downstaged 5 (83%) 12 (46%) —
Not downstaged 1 (17%) 14 (54%) 0. 18
Path response
 ≥90% 4 (57%) 7 (21%) —
 <90% 3 (43%) 27 (79%) 0.069
3-yr RFS all 63% 53% 0.43
3-yr RFS IIIA 57% 39% 0.32
3-yr OS all 60% 60% 0.83
3-yr OS IIIA 57% 44% 0.48
KRAS-mutant  
(n = 10)
KRAS wild-type  
(n = 31)
—
Downstaged 5 (50%) 14 (45%) —
Not downstaged 5 (50%) 17 (55%) 1.0
Nodal downstaged 5 (63%) 12 (50%) —
Not downstaged 3 (37%) 12 (50%) 0.69
Path response
≥90% 0 (0%) 11 (35%) —
<90% 10 (100%) 20 (65%) 0.039
3-yr RFS all 35% 65% 0.14
3-yr RFS IIIA 17% 56% 0.096
3-yr OS all 33% 72% 0.036
3-yr OS IIIA 17% 61% 0.068
RFS, recurrence-free survival; OS, overall survival.
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experiencing the best outcomes. In a more recent publication 
of 192 patients with NSCLC, who received neoadjuvant 
chemotherapy, the long-term OS and RFS of the 19% of 
patients with tumors demonstrating 90% or more pathological 
response were significantly different than those with less than 
90% response.22 Although our pathological response data must 
be interpreted cautiously as an unplanned and exploratory 
analysis, the 27% of resected patients who had tumors with 
90% or more pathologic response had a 3-year RFS of 91% 
versus 48% in those with less than 90% pathologic response.
This trial would suggest that patients without a major 
pathologic response are at high risk for recurrence and may be 
ideal candidates for additional therapy potentially, as informed 
by an analysis of their tumor tissue. It is intriguing to note that 
in the 10 patients with KRAS-mutant lung cancer who under-
went resection, there were no major pathological responses. 
These patients may be appropriate for studies of targeted neo-
adjuvant or alternative adjuvant approaches.
Given the paucity of single-agent bevacizumab data in 
NSCLC, we administered bevacizumab alone followed by 
repeat imaging 2 weeks later. This short interval was chosen so 
that there is no substantial delay in the administration of cyto-
toxic chemotherapy. We found tumor regression with single-
agent bevacizumab and tumor cavitation in 18% of patients. 
Fifty-seven percent of patients with tumor cavitation had a 
major pathologic response compared with 21% of patients 
without cavitation. Given the small sample size these data were 
not significant but are, nevertheless, intriguing. Cavitation has 
been described with bevacizumab, and a new set of response 
criteria for radiographic assessment to account for the develop-
ment of cavitation have been proposed23; however, the associa-
tion with pathologic response has not been previously reported. 
Identification of a predictor of intratumoral cavitation could 
allow us to contemplate a biomarker for angiogenesis inhibi-
tors, which to date has not been well established.
In the era of personalized therapies for the treatment of 
NSCLC, neoadjuvant approaches permit individual patient 
assessment of treatment efficacy. Future trials will incorporate tar-
geted therapies as part of a neoadjuvant strategy based on molecu-
lar profile, with the goal of improving pathologic response beyond 
what is currently achievable, with unselected standard cytotoxic 
chemotherapy. Adaptive strategies to improve outcomes in those 
who are unlikely to respond (lack of cavitation with bevacizumab 
or KRAS mutation) or those who do fail to respond to neoadjuvant 
therapy (lack of pathologic response) should be considered.
This study was sponsored by a research grant from 
Genentech.
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